Protecting the Primary Endpoint: Ensuring Data Integrity in Immunology & Inflammation Clinical Trials

By Mila Grieg, MD, PhD (Vice President, Medical Affairs, ACE Therapeutic Strategy Head, Immunology & Inflammation)

Why Endpoint Protection Matters

Immunology and inflammation (I&I) studies frequently rely on complex clinical assessments, composite disease activity scores, imaging evaluations, endoscopic findings, histopathology interpretations, and biomarker measurements to demonstrate treatment benefit. Unlike laboratory values that can be measured objectively, many efficacy endpoints in I&I trials depend on human assessment and interpretation, creating opportunities for variability that can influence study outcomes. 

As clinical development programs become global and involve a large number of investigators, sites, and evaluators, maintaining consistency in endpoint assessment has become a critical component of trial quality. Variability introduced through inconsistent scoring, differing interpretation standards, or site-level assessment drift can dilute treatment effects, increase placebo responses, and ultimately affect the ability of a study to demonstrate efficacy. 

Therefore, successful immunology clinical trials involve not only the selection of relevant endpoints, but also rigorous procedures to ensure that those endpoints are protected and evaluated consistently throughout the study duration. 

Why Immunology & Inflammation Study Endpoints Are Particularly Vulnerable 

Many of the most common endpoints used in Immunology and Inflammation studies are largely subjective and/or involve multiple levels of interpretation. 

Physical examination and clinical judgment are critical for assessment of tender and swollen joint counts in rheumatology investigations. Dermatology endpoints including Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and Psoriasis Area and Severity Index (PASI) are based on visual assessment and lesion characterization. Commonly used in lupus investigations are composite measures like SRI-4 and BICLA, which combine numerous clinical and laboratory components. Gastrointestinal investigations that depend on endoscopic and histologic findings typically require interpretation by qualified experts. 

Even if individual raters are very skilled, variability may be introduced by deviations in technique, interpretation or scoring standards. Scoring drift may occur during a long study as investigators inadvertently or unconsciously adjust their assessment methods. Such challenges are even more apparent in global studies where different healthcare systems, clinical practices and patient demographics are included. 

The consequence is a simple but important reality: endpoint variability can become one of the biggest threats to data quality and treatment signal detection in immunology clinical trials. 

Protecting the Primary Endpoint

Since several I&I endpoints depend on consistent human assessment including joint counts, skin scores, endoscopic grading, histology reads, etc., even small amounts of inter-rater variability can blur a true treatment effect or inflate placebo response, putting a program at risk.  

We carry out endpoint protection across three pillars, applied from protocol design through database lock. 

• Rater training, certification and standardization: Operator-dependent scores are among the largest sources of variability in I&I trials. We build rater qualification and ongoing calibration into study conduct for instruments such as tender/swollen joint counts (RA, PsA), the modified Rodnan Skin Score (systemic sclerosis), IGA/EASI/PASI (atopic dermatitis, psoriasis), SLEDAI/BILAG (lupus), and acute/chronic GVHD grading; reducing drift across sites, regions and visits. 
• Central imaging, endoscopy and histopathology read: For endpoints that regulators expect to be read centrally and blinded, we coordinate independent central reads: blinded central endoscopy reading for IBD (SES-CD, Mayo endoscopic subscore, UCEIS), central histopathology (Geboes/Robarts in UC, peak eosinophil counts in EoE), central dermatology image review, central spirometry over-read in respiratory studies, and renal biopsy reading in lupus nephritis. 
• Biomarker and translational capabilities: Our clinical pharmacology, biomarker and translational teams integrate objective measures alongside clinical scores: autoantibody and complement panels (ANA, anti-dsDNA, anti-CCP, C3/C4), inflammatory markers (CRP, ESR, fecal calprotectin), type I interferon signatures, eosinophils and FeNO, plus immunogenicity (anti-drug and neutralizing antibody) assessment essential to biologic and biosimilar programs. This pairing of validated clinical endpoints with mechanistic biomarkers strengthens the evidence package and de-risks regulatory interactions. 

Applying Endpoint Protection Across Immunology Indications

While the principles of endpoint protection are the same, the operational challenges differ across indications. Each disease category has its own efficacy assessments, specialized processes, and objective measures. Disease-specific approaches are needed to minimize variability and ensure data quality. 

A review of common indications in immunology shows that endpoint protection measures must be modified to the respective endpoints used.

Different indications require different clinical assessments, imaging modalities, histologic assessments, and biomarker tests, each of which has different sources of variability that need to be managed to produce valid efficacy data. 

For example, research in rheumatology and dermatology generally includes clinical scores evaluated by the investigators, and so rater training and uniformity are critical. In gastrointestinal diseases such as Crohn’s disease and ulcerative colitis, central endoscopy and histopathology review help to reduce variability in interpretation, while lupus and other systemic autoimmune diseases often incorporate biomarker panels and central pathology assessments to complement complex clinical endpoints. Respiratory and allergy studies similarly benefit from centralized review processes and objective measures such as eosinophil counts, FeNO, and IgE levels. 

Although the exact endpoint may differ from indication to indication, the purpose is consistent: to minimize variability, preserve treatment signals, and generate high-quality evidence that endures regulatory scrutiny and facilitates confident decision-making throughout clinical development. 

The Evolution of Endpoint Protection in Immunology & Inflammation Trials

With continued growth in immunology clinical trials, to gain confidence in efficacy outcomes, biopharma sponsors are looking beyond conventional clinical assessments. Biomarkers, imaging technologies, and translational analyses offer objective evidence that may supplement clinical scores, confirm biological activity, support the interpretation of treatment effects, and provide insights into mechanisms of action. In several indications, inflammatory biomarkers, autoantibody profiles, eosinophil counts and molecular signatures are becoming useful tools for patient stratification, response assessment and building a deeper understanding of therapeutic benefits. 

At the same time, technological advances are generating new options to reduce variability and improve endpoint consistency. Digital data capture platforms, electronic clinical outcome assessments (eCOAs) and remote monitoring technologies are making it possible to standardize data gathering across facilities and patient populations. Artificial intelligence and machine learning have emerging applications that support image analysis and pattern recognition. These applications have the potential to increase consistency and identify assessments that may require further investigation. These advancements, coupled with advances in translational science and multi-omics methods, provide a more objective and data-driven approach to efficacy evaluation. 

These developments come at a time of heightened regulatory scrutiny of endpoint reliability, data integrity and assessment uniformity. Regulatory authorities expect sponsors to demonstrate that efficacy endpoints were monitored consistently and that possible sources of bias and variability were proactively addressed. Endpoint protection is no longer a quality control exercise, but an essential component of generating credible evidence, preserving treatment signals, and supporting successful regulatory and clinical development outcomes. 

Conclusion

The success of an immunology trial depends on more than selecting the right endpoint, it depends on ensuring that endpoint is measured consistently, objectively, and reproducibly throughout the study. 

Through structured rater training and certification, centralized and blinded review processes, and integration of objective biomarkers, sponsors can reduce variability, improve data quality, and strengthen confidence in treatment effects. As immunology clinical trials continue to evolve in complexity, endpoint protection has become a fundamental component of clinical trial execution, helping transform high-quality assessments into high-quality evidence. 

At Allucent, endpoint protection is embedded throughout our Immunology & Inflammation programs through indication-specific expertise, standardized operational processes, objective endpoint assessment, and proactive quality oversight.  

Contact us to learn more about our capabilities and how we help sponsors generate high-quality, reliable clinical evidence to bring their new immunology & inflammation therapies to light.